

Key Financial Highlights FY21

Year ended 30 June (\$m)	2021	2020	Variance	
<i>Results from operations including one time adjustments*</i>				
Revenue	16,927	14,169	2,758 ↑	19.5%
EBITDA	2,718	788	1,930 ↑	244.9%
NPAT	2,103	(1,919)	4,022 ↑	209.6%
Basic earnings per share	0.9¢	(0.8¢)	1.7¢ ↑	212.5%

❖ Year-on-year Revenue growth of 19.5% to \$16.9 million (which includes \$0.9 million of JobKeeper receipts)

❖ Positive EBITDA achieved for full year 2021 which represents a year-on-year improvement of 244.9%*

❖ Year-on-year increase in earnings per share of 212.5%

❖ Strong cash balance of \$6.9 million

Key Business Highlights



❖ Corporate

- Restored IDT to profitability, recording the Company's first operating profit since 2009.
- Circa 200% year-on-year increase in net profit after tax from a loss of \$1.9m in FY'20 to a profit of \$2.1m in FY'21.

❖ COVID-19 Vaccine and Therapeutic Initiatives

- Positioning IDT to leverage its existing TGA and FDA accredited pharmaceutical manufacturing facilities and capabilities to assist with the supply chain challenges brought about by the COVID-19 pandemic.
- Letter Agreement finalised in August 2021 with the Australian Government, Department of Health to bring IDT's cGMP sterile manufacturing facility into a state of readiness.
- IDT has engaged with the Victorian Government and Monash Institute of Pharmaceutical Sciences (MIPS) to cGMP manufacture MIPS' mRNA COVID-19 receptor binding domain vaccine which will be Australia's first locally developed mRNA COVID-19 vaccine candidate.
- Engaged with Industry and formed an Alliance with Monash and Australian National Universities to build an mRNA ecosystem underpinning IDT's submission to the Australian Government's Onshore mRNA Manufacturing Capability: Approach To Market (ATM).

❖ Medicinal Cannabis Manufacturing Plan

- The Company has developed its own proprietary medicinal cannabis API and finished dose form products, several of which are now commercially available.